The Cancer Prevention and Research Institute of Texas (CPRIT) Fiscal Year 2010 Funding Opportunities Announced
| Program Title | Fiscal year 2010 funding opportunities |
|---|---|
| Funding Agency | Cancer Prevention and Research Institute of Texas (CPRIT) |
| Website | http://www.cprit.state.tx.us/funding.html |
| Due Date | Oct 08, 2009 03:00 PM |
http://www.cprit.state.tx.us/pdfs/rfa_r-10-i1.pdf
http://www.cprit.state.tx.us/funding.html
Online
application opens September 15, 2009, 7 a.m. Central Time; Application
due October 8, 2009, 3 p.m. Central Time; Application review December
2009/January 2010; Award notification January/February 2010;
Anticipated start date February/March 2010
Applicants may request a maximum of $1,000,000 in total costs per year for up to 4 years.
The goal of awards made in response to this RFA is to fund exceptionally innovative research projects with great potential impact that are directed by a single investigator. This award allows experienced cancer researchers the opportunity to explore new methods and approaches for investigating a question of importance that has been inadequately addressed or for which there may be an absence of an established paradigm or technical framework. Applicants need not be trained specifically in cancer research. However, successful applicants should be working in a research environment capable of supporting potentially high-impact studies. Access to a clinical environment and interaction with translational cancer physician-scientists are highly desirable.
Areas of interest include laboratory research, translational studies, and/or clinical investigations.In that cancers arise from a large number of derangements of basic molecular and cellular functions and in turn cause many alterations in basic biological processes, almost any aspect of biology may be relevant to cancer research, more or less directly. The degree of relevance to cancer research will be an important criterion for evaluation of projects for funding by CPRIT. For example, are alterations in the process in question primarily responsible for oncogenesis or secondary manifestations of malignant transformation? Will understanding the process or interfering with it offer selective and useful insight into prevention, diagnosis, or treatment of cancer? Successful applicants for funding from CPRIT will have addressed these questions satisfactorily.
